Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 8899 results

  1. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

    Technology appraisal guidance
    Awaiting development

  2. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development Reference number: GID-TA11091 Expected publication date:  22 April 2026

    Technology appraisal guidance
    In development

  3. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 24 February 2026.

    Technology appraisal guidance
    In consultation

  4. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]

    Awaiting development Reference number: GID-TA11920 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma [ID6701]

    Awaiting development Reference number: GID-TA11935 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  8. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor

    In development Reference number: GID-IPG10441 Expected publication date: TBC

    Interventional procedures guidance
    In development

  9. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 11 February 2026.

    Interventional procedures guidance
    In consultation

  10. Aggressive behaviour in people receiving NHS or social care: prevention and management

    In development Reference number: GID-NG10432 Expected publication date:  28 January 2027

    NICE guideline
    In development

  11. Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death

    Awaiting development Reference number: GID-IPG10437 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  12. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    In development Reference number: GID-TA11468 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 26 February 2026.

    Technology appraisal guidance
    In consultation

  15. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  08 October 2027

    NICE guideline
    In development